% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • zwerp2000 zwerp2000 Apr 2, 2013 6:34 PM Flag

    Cramer mentions SRPT

    Sarepta is largely a bet on a drug called Eteplirsen, which is sued to treat Duchenne muscular dystrophy, a rare genetic condition that leaves patients wheelchair bound by their teens.

    "Back in October, Sarepta spiked up to nearly $45 on some downright miraculous clinical trial results, showing that their drug actually improved patients' ability to walk—I say miraculous because the current treatments for this disease only slows down the deterioration, other drugs don't reverse it," Cramer explained.

    Currently, Sarepta is trying to file for accelerated approval with the FDA in order to skip phase 3 trials, "that's a bold move that tells me just how revolutionary this drug could be," Cramer added.

    "We'll likely get more clarity on this by the end of the month," Cramer explained and therefore the environment is somewhat binary.

    That is, if the FDA says yes, the stock could roar. However, if the FDA refuses and Sarepta has to spend time doing additional trials, the stock could decline sharply.

    * If the scenario outlined above presents too much risk, but you remain interested, Cramer suggested waiting for the FDA decision. If it's negative and the stock declines, he suggests buying weakness because he thinks the long-term opportunity remains strong. Of course if it's positive, you'd have no entry point.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Great session from Cramer. He was a little reserved back in Sept, wanted a pull-back in Oct, but tonight he was double bullish! He likes their chances short-term and long. If they get an accelerated path, "this stock will roar!" If it pulls back on bad news, he says buy the weakness. That is about as bullish as one can be. Good luck longs, our time must be near. This could be a the greatest advance in health that we see in our lifetime. The antisense platform will provide the strongest path to personalized healthcare. This is what all of big pharma is dreaming about.

      Sentiment: Strong Buy

    • Tomorrow should be fun

      Sentiment: Strong Buy

13.21-0.21(-1.56%)Apr 27 4:00 PMEDT